Quality by design development of folic acid–engineered berberine nanoliposomes for targeted triple-negative breast cancer therapy

Triple-negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes due to the lack of actionable molecular targets and the systemic toxicity associated with standard chemotherapy. Berberine chloride (BBR), a plant-derived isoquinoline alkaloid, exhibits promising anticancer activity; however, its poor solubility and limited bioavailability restrict therapeutic utility. In this study, folic acid–decorated nanoliposomes were developed to enhance the targeted delivery of BBR to TNBC cells. BBR-loaded liposomes and folic acid–functionalized liposomes were prepared using the solvent injection method and optimized through a Quality-by-Design (QbD) framework. The optimized folate-modified formulation showed a mean particle size of 168.3 nm with an entrapment efficiency of 41.8%, while non-targeted liposomes exhibited a smaller size (95.6 nm) and slightly higher drug loading (47.5%). Both systems provided sustained drug release over 72 hours, with folate-decorated liposomes demonstrating a more controlled release pattern. Cytotoxicity studies in MDA-MB-231 cells revealed significantly enhanced antiproliferative activity of folate-functionalized nanoliposomes (IC₅₀ = 24.72 μM) compared to non-targeted liposomes and free BBR. Increased intracellular reactive oxygen species generation following folate-mediated delivery suggested oxidative stress–driven cell death as a contributing mechanism. Importantly, genotoxicity evaluation using Drosophila melanogaster confirmed the safety of the liposomal formulations. Overall, folic acid–decorated nanoliposomes substantially improve the therapeutic efficacy of berberine and offer a rational, targeted nanocarrier approach for TNBC management.

Authors

Institutions

Publication Details

Journal
Naunyn-Schmiedeberg s Archives of Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.1007/s00210-026-06037-7
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Quality by design development of folic acid–engineered berberine nanoliposomes for targeted triple-negative breast cancer therapy

Saurabh Mittal, Sushama Talegaonkar, Namrata Gautam, Disha Mittal et al.
3 links
Naunyn-Schmiedeberg s Archives of Pharmacology
Nanoparticle-Based Drug Delivery
article

Quality by design development of folic acid–engineered berberine nanoliposomes for targeted triple-negative breast cancer therapy

Saurabh Mittal, Sushama Talegaonkar, Namrata Gautam, Disha Mittal, Anita Kamra Verma, Debopriya Dutta, Karishma Niveria, Surajita Sahu, Roshni Singh, Meenakshi Tanwar
article en

Abstract

Triple-negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes due to the lack of actionable molecular targets and the systemic toxicity associated with standard chemotherapy. Berberine chloride (BBR), a plant-derived isoquinoline alkaloid, exhibits promising anticancer activity; however, its poor solubility and limited bioavailability restrict therapeutic utility. In this study, folic acid–decorated nanoliposomes were developed to enhance the targeted delivery of BBR to TNBC cells. BBR-loaded liposomes and folic acid–functionalized liposomes were prepared using the solvent injection method and optimized through a Quality-by-Design (QbD) framework. The optimized folate-modified formulation showed a mean particle size of 168.3 nm with an entrapment efficiency of 41.8%, while non-targeted liposomes exhibited a smaller size (95.6 nm) and slightly higher drug loading (47.5%). Both systems provided sustained drug release over 72 hours, with folate-decorated liposomes demonstrating a more controlled release pattern. Cytotoxicity studies in MDA-MB-231 cells revealed significantly enhanced antiproliferative activity of folate-functionalized nanoliposomes (IC₅₀ = 24.72 μM) compared to non-targeted liposomes and free BBR. Increased intracellular reactive oxygen species generation following folate-mediated delivery suggested oxidative stress–driven cell death as a contributing mechanism. Importantly, genotoxicity evaluation using Drosophila melanogaster confirmed the safety of the liposomal formulations. Overall, folic acid–decorated nanoliposomes substantially improve the therapeutic efficacy of berberine and offer a rational, targeted nanocarrier approach for TNBC management.

Naunyn-Schmiedeberg s Archives of Pharmacology
University of Delhi (IN), Galgotias University (IN), National Institute of Technology Rourkela (IN), Amity University (IN), Delhi Pharmaceutical Science and Research University (IN)
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon